Nalaganje...
A case of class 3 MEK1 mutated metastatic colorectal cancer with a non-durable tumor marker response to MEK and ERK inhibitors
Class 3 MEK1 mutations disrupt the negative regulatory helix region of MEK1 and drive constitutive activation of both pMEK and pERK that is independent of RAF and of MEK phosphorylation. Targeting MEK with trametinib resulted in mixed clinical responses in class 3 MEK1 mutated Langerhans cell histio...
Shranjeno v:
| izdano v: | J Gastrointest Oncol |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
AME Publishing Company
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6954994/ https://ncbi.nlm.nih.gov/pubmed/31949931 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2019.08.02 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|